Leukemic cells and aberrant phenotypes in acute leukemia patients: A flow cytometry analysis

Neoplasma

Volumn 50, Issue 6, 2003, Pages 422-427

  Voskova D ^a   Valekova L ^a   Fedorova J ^a   Hudecek J ^a   Kubisz, P ^a  

^a University Teaching Hospital in Martin   (Slovakia)

Author keywords

Acute leukemia; Flow cytometry; Leukemia associated immunophenotype; Minimal residual disease

Indexed keywords

MONOCLONAL ANTIBODY;

ABERRANT PHENOTYPE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; B LINEAGE ACUTE LYMPHOCYTIC LEUKEMIA; BLAST CELL; CANCER CLASSIFICATION; CELL HETEROGENEITY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DOUBLE STAIN FLOW CYTOMETRY; EUROPEAN GROUP FOR IMMUNOLOGICAL CLASSIFICATION OF LEUKEMIA; FAB CLASSIFICATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE; LEUKEMIA ASSOCIATED PHENOTYPE; LEUKEMIA CELL; MALE; MINIMAL RESIDUAL DISEASE; MULTIPARAMETRIC FLOW CYTOMETRY; PHENOTYPE; PROSPECTIVE STUDY; STAINING; T CELL LEUKEMIA; T LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA;

EID: 18744434194     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. BABUŠÍKOVÁ O, GLASOVÁ M, KONÍ KOVÁ E, KUSENDA J. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia. Neoplasma 1996; 43: 367-372.
2. BABUŠÍKOVÁ O, KONÍKOVÁ E, KUSENDA J, KOUBEK K. Aberrant marker expression in T- and B-lymphoid and myeloid leukaemia cells of different differentiation stages. Neoplasma 1999; 46: 277-282.
3. BENE MC, CASTOLDI G, KNAPP W, LUDWIG WD, MATUTES E, ORFAO A, VAN'T VEER MB. Proposals for the immunological classification of acute leukaemias. The European Group for the Immunological Characterisation of Leukaemias (EGIL). Leukemia 1995; 9: 1783-1786.
4. BENNETT JM, CATOVSKY D, DANIEL MT, FLANDRIN G, GALTON DAG, GRALNICK HR, SULTAN C. Proposals for the classification of acute leukemias. A report of the French-American-British Cooperative Group. Br J Haematol 1976; 33: 451-458.
5. BRADSTOCK KF, KIRK J, GRIMSLEY PG, KABRAL A, HUGHES WG. Unusual immunophenotypes in acut leukaemias: incidence and clinical correlations. Br J Haematol 1989; 72: 512-518.
6. CAMPANA D, COUSTAN-SMITH E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152.
7. CAMPANA D, BEHM FG. Immunophenotyping of leukaemia. Journal of Immunological Methods 2000; 243: 59-75.
8. CAMPANA D, YOKOTA S, COUSTAN-SMITH E, HANSEN-HAGGE TE, JANOSSY G, BARTRAM CR. The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study. Leukemia 1990; 4: 609-614.
9. CIDAUD J, SAN MIGUEL JF, LOPEZ-BERGES MC, VIDRIALES B, VALVERDE B, OCQUETEAU M, MATEOS G, CABALLERO MD, HERNANDEZ J, MORO MJ, MATEOS MV, ORFAO A. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 3774-3781.
10. COUSTAN-SMITH E, BEHM FG, HURWITZ CA, RIVERA GK, CAMPANA D. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993; 7: 853-858.
11. DRACH J, DRACH D, GLASSL H, GATTRINGER C, HUBER H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13: 893-901.
12. DWORZAK MN. Immunological detection of minimal residual disease in acute lymphoblastic leukemia. Onkologie 2001; 24: 442-448.
13. European Working Group on Clinical Cell Analysis (EWGCCA). Consensus document on leukemia immunophenotyping. Leukemia 1996; 10: 877-895.
14. GARCIA VELA JA, MONTESERIN MC, DELGADO I, BENITO L, ONA F. Aberrant immunophenotypes detected by flow cytometry in acute lymphoblastic leukemia. Leuk Lymphoma 2000; 36: 275-284.
15. GRIESINGER F, PIRÓ-NOACK M, KAIB N, FALK M, RENZIENHAUSEN A, TROFF C, GROVE D, SCHNITTGER S, BÜCHNER T, RITTER J, HIDDEMANN W, WÖRMANS B. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol 1999; 105: 241-255.
16. GORE SD, KASTAN MB, GOODMAN SN, CIVIN CI. Detection of minimal residual T cells acute lymphoblastic leukemia by flow cytometry. J Immunol Methods 1990; 132: 275-286.
17. KERN W. Einsatz der multiparametrischen Durchflusszytometrie zur Identifizierung von Prognoseparametern bei der akuten myeloischen Leukämie: Erfassung von Antigenex-pressionsmustern bei Diagnosestellung und Quantifizierung minimaler Resterkrankung im Behandlungsverlauf. Habilitationschrift 2003: 54-59.
18. MACEDO A, ORFÁO A, VIDRIALES MB, LÓPEZ-BERGES MC, VALVERDE B, GONZÁLEZ MD, CABALLERO MD, RAMOS F, MARTÍNEZ M, FERNÁNDEZ-CALVO J, MARTÍNEZ A, SAN MIGUEL JF. Characterisation of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995; 70: 189-194.
19. MACEDO A, ORFÁO A, GONZALEZ M, VIDRIALES MB, LóPEZBERGES MC, MARTÍNEZ A, SAN MIGUEL JF. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995; 9: 993-998.
20. NAKAMURA K, OGATA K, AN E, DAN K. Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia. Br J Haematol 2000; 108: 710-716.
21. NEALE GA, COUSTAN-SMITH E, PAN Q, CHEN X, GRUHN B, STOW P, BEHM FG, PUI CH, CAMPANA D. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 1221-1226.
22. ORFAO A, CIDAUD J, LOPEZ-BERGES MC, LOPEZ A, VIDRIALES B, CABALLERO MD, VALVERDE B, GONZALES M, SAN MIGUEL JF. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma 1994; 13: 87-90.
23. PAIETTA E, ANDERSEN J, GALLAGHER R, BENNETT J, YUNIS J, CASSILETH P, ROWE J, WIERNIK PH. The immunophenotype of acute promyelotic leukemia (APL): an ECOG study. Leukemia 1994; 8: 1108-1112.
24. PAREDES-AQUILERA R, ROMERO-GUZMAN L, LOPEZ-SANTIAGO N, BURBANO-CERON L, CAMACHO-DEL MONTE O, NIETO-MARTINEZ S. Flow cytometric analysis of cell-surface and intracellular antigens in the diagnosis of acute leukemia. Am J Hematol 2001;68:69-74.
25. PLATA E, CHOREMI-PAPADOPOLOU H, VIGLIS V. Flow-cytometric detection of minimal residual disease with atypical antigen combinations in patients with de novo acute myeloid leukemia. Ann Hematol 2000; 79: 543-546.
26. PUI CH, EVANS WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
27. RADICH JP. Clinical applicability of the evaluation of minimal residual disease in acute leukemia. Curr Opin Oncol 2000; 12: 36-42.
28. READING CL, ESTEY EH, HUH YO, CLAXTON DF, SÁNCHEZ G, TERSTAPPEN LWMM, O, BRIEN MC, BARON S, DEISSEROTH AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
29. TERSTAPPEN LWMM, KOENEMANN S, SAFFORD M, LOKEN MR, ZURLUTTER K, BUECHNER T, HIDDEMANN W, WOERMANN B. Flow cytometric characterisation of acute myeloid leukemia. Part II. Phenotypic heterogenity at diagnosis. Leukemia 1991; 5: 757-767.
30. TERSTAPPEN LWMM, KOENEMANN S, SAFFORD M, LOKEN MR, ZURLUTTER K, BÜCHNER T, HIDDEMANN W, WÖRMANN B. Flow cytometric characterisation of acute myeloid leukemia. Part I. Significance of light scattering properties. Leukemia 1991; 5: 315-321.
31. TERSTAPPEN LWMM, LOKEN MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assesessed by multi-dimensional flow cytometry. Analytical Cellular Pathology 1990; 2: 229-240.
32. VAN DONGEN JJ, SZCZEPANSKI T, DE BRUIJN MA, VAN DEN BEEMD MW, DE BRUIN-VERSTEEG S, WIJKHUIJS JM, TIBBE GJ, VAN GASTEL-MOL EJ, GROENEVELD K, HOOIJKAAS H. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2: 121-133.
33. VENDITTI A, BUCCISANO F, DEL POETA G, MAURILLO L, TAMBURINI A, Cox C, BATTAGLIA A, CATALANO G, DEL MORO B, CUDILLO L, POSTORINO M, MASI M, AMADORI S. Level of minimal residual disease after consolitation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952.
34. VOŠKOVÁ D, VÁLEKOVÁ L', KUBISZ P. Recent findings in the diagnosis of minimal residual disease in acute leukemias, focused on flow cytometry (in Slovak). Vnitřní lékařství 1997;43:332-336.